This is a regulatory disclosure informing of the adjournment of a previously scheduled Board of Directors meeting. The meeting, initially set for Thursday, May 28, 2026, was intended to consider and approve the Audited Standalone Financial Results for the quarter and year ended March 31, 2026.
The meeting was adjourned because the financial results were not approved by the company's Audit Committee. The reason cited for this non-approval was a delay in the preparation of the Financial Statement. Consequently, the Audit Committee meeting has been adjourned until Saturday, May 30, 2026.
The Board Meeting is also now adjourned to the same date, Saturday, May 30, 2026. Its purpose remains to consider and approve the Audited Standalone Financial Results for the Quarter and Financial Year ended March 31, 2026. The results will be submitted and published to the exchanges only after they receive formal approval from the Board at this adjourned meeting.
Furthermore, the company confirms that the Trading Window for dealing in the equity shares of the company for all Designated Persons will remain closed. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, and the company's internal Code of Conduct. The trading window will reopen only after the expiry of 48 hours from the time the financial results are made public on the revised date. This continues the closure previously communicated in letters dated March 30, 2026, and May 22, 2026.
The disclosure was signed by Rahul Kumar Jariwala, Company Secretary and Compliance Officer (Membership No: A70164), on behalf of Trident Texofab Limited.